Health Care·Biotechnology·$79.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $11.44 | N/A | +38.18% |
management commentary, guidance changes, and full analysis available with Pro.
| +38.18% |
Tone: Cautiously Optimistic
Overall, management expressed confidence in their product pipeline and the company's ability to navigate market challenges. However, they acknowledged the competitive landscape.
Management highlighted strong performance in key products.
They emphasized ongoing investment in R&D to drive future growth.
Regeneron Pharmaceuticals reported strong earnings per share, exceeding expectations significantly. However, the stock fell by 1.07% in reaction to the lack of revenue data and guidance. Investors may be cautious due to the absence of future projections, despite the positive EPS surprise.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
UNITEDHEALTH GROUP I
Jan 27, 2026